Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer-Reference-Cited by-同舟云学术

Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer

Published:2021-09-01 Issue:9 Volume:7 Page:1360
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Hatschek Thomas¹²,Foukakis Theodoros¹²,Bjöhle Judith¹,Lekberg Tobias¹,Fredholm Hanna¹³,Elinder Ellinor⁴,Bosch Ana⁵,Pekar Gyula⁶,Lindman Henrik⁷,Schiza Aglaia⁸,Einbeigi Zakaria⁹,Adra Jamila¹⁰,Andersson Anne¹¹,Carlsson Lena¹²,Dreifaldt Ann Charlotte¹³,Isaksson-Friman Erika¹⁴,Agartz Susanne²,Azavedo Edward¹⁵,Grybäck Per¹⁶,Hellström Mats¹⁷,Johansson Hemming¹⁷,Maes Claudia¹⁷,Zerdes Ioannis²,Hartman Johan²,Brandberg Yvonne²,Bergh Jonas¹²

Affiliation:

1. Breast Cancer Center, Karolinska University Hospital, Stockholm, Sweden

2. Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden

3. Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden

4. Department of Oncology, South Hospital, Stockholm, Sweden

5. Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden

6. Department of Pathology, Skåne University Hospital, Lund, Sweden

7. Department of Oncology, Uppsala University Hospital, Uppsala, Sweden

8. Department of Immunology, Genetics and Pathology, Uppsala University Hospital, Uppsala, Sweden

9. Department of Oncology, Southern Älvsborg Hospital, Borås, Sweden

10. Department of Oncology, Sahlgrenska University Hospital, Göteborg, Sweden

11. Department of Radiation Sciences, Oncology Unit, Umeå University Hospital, Umeå, Sweden

12. Department of Oncology, Sundsvall Hospital, Sundsvall, Sweden

13. Department of Oncology, Örebro University Hospital, Örebro, Sweden

14. Department of Oncology, St Göran Hospital, Stockholm, Sweden

15. Department of Radiology, Karolinska University Hospital, Stockholm, Sweden

16. Department of Nuclear Medicine, Karolinska University Hospital, Stockholm, Sweden

17. Central Trial Office, Clinical Trial Unit, Karolinska University Hospital, Stockholm, Sweden

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2781086/jamaoncology_hatschek_2021_oi_210027_1631288575.60072.pdf

Reference22 articles.

1. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.;Cortazar;Lancet,2014

2. Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes: a meta-analysis.;Broglio;JAMA Oncol,2016

3. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.;Gianni;Lancet Oncol,2012

4. Trastuzumab emtansine for residual invasive HER2-positive breast cancer.;von Minckwitz;N Engl J Med,2019

5. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.;van Ramshorst;Lancet Oncol,2018

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of [18F]FDG PET/CT in patients with no special type breast cancer: Literature review and comparison between guidelines;The Breast;2024-09

2. De-escalation of neoadjuvant taxane and carboplatin therapy in HER2-positive breast cancer with dual HER2 blockade: a multicenter real-world experience in China;World Journal of Surgical Oncology;2024-08-21

3. 18F-FDG PET/CT for early prediction of pathological complete response in breast cancer neoadjuvant therapy: a retrospective analysis;The Oncologist;2024-07-23

4. Neoadjuvant T-DM1 for HER2-positive breast cancer used as a bridging strategy during COVID-19 pandemic: lessons learned—a case series;Gland Surgery;2024-06

5. Longitudinal molecular profiling elucidates immunometabolism dynamics in breast cancer;Nature Communications;2024-05-07